Brazil strikes deal with Chinese lab for producing vaccine against COVID-19

9,000 Brazilians to particiapte in trials

June 12, 2020 02:39 am | Updated 02:55 am IST - Rio De Janeiro

Health workers treat a patient at Parque dos Atletas field hospital in Rio de Janeiro on June 8.

Health workers treat a patient at Parque dos Atletas field hospital in Rio de Janeiro on June 8.

The Sao Paulo government announced on June 11 that Brazil’s Instituto Butantan reached an agreement with the Chinese laboratory Sinovac Biotech to produce an experimental vaccine against COVID-19.

Some 9,000 Brazilians will participate in tests beginning in July, representing the third and last stage of testing before distribution. If the vaccine is effective, it will be produced in Brazil. Sao Paulo Gov. Joao Doria said the vaccine could be available in the first half of 2021.

“Today is a historic day for Sao Paulo, Brazil and world science. The vaccine that Butantan will produce is one of the most advanced,” Mr. Doria said at a press conference. He said he hoped it can be used to immunize millions of Brazilians.

Also read:When will a COVID-19 vaccine be ready?

The experimental vaccine has already passed two stages of testing in China, where it was given to monkeys and then to 744 Chinese volunteers.

Dimas Covas, director of Butantan, said the vaccine is in the group of the 10 most advanced, among more than 100 that are being developed worldwide.

Also read:Coronavirus | Brazil's biggest cities start reopening as COVID-19 surges

Separately, Brazil will begin this month to test a vaccine produced by the University of Oxford, also considered one of the most promising and in an advanced stage of trials. Some 2,000 Brazilians will be selected to participate in Sao Paulo and Rio de Janeiro, in a project coordinated by the Federal University of Sao Paulo.

Brazil has reported more than 39,600 deaths from COVID-19. Many experts believe the toll is higher than the official count .

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.